On Jun. 11, 2020, Atossa Therapeutics announced that the manuscript of the results from in vitro testing of AT-H201, Atossaﾒs proprietary COVID-19 drug candidate was published preprint through ResearchGate. The preliminary study results showed that AT-H201 inhibits SARS-CoV-2 infectivity of VERO cells in a laboratory culture, which is a standard cell type being used to study infectivity of the coronavirus.